Violich Capital Management Inc. Increases Stake in Eli Lilly and Company $LLY

Key Points

• Violich Capital Management increased its Eli Lilly stake by 151% in the third quarter, ending with 3,241 shares valued at approximately $3.75 million. Institutional investors collectively own 82.53% of LLY.
• Eli Lilly reported strong quarterly performance, with revenue rising 47.7% year over year to $22.97 billion and EPS of $8.38, well above analyst expectations. Its obesity-treatment pipeline and strong demand for Zepbound and other weight-loss medicines continue to support growth prospects.
• Analysts maintain a generally positive outlook, with a “Moderate Buy” consensus and an average price target of $1,311.96, although the stock’s elevated valuation remains a concern. Two executives also sold shares under pre-arranged Rule 10b5-1 plans, totaling about $15.96 million over the past 90 days.

Violich Capital Management Inc. raised its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 151.0% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,241 shares of the company's stock after acquiring an additional 1,950 shares during the quarter. Violich Capital Management Inc.'s holdings in Eli Lilly and Company were worth $3,750,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of LLY. Miller Global Investments LLC grew its holdings in Eli Lilly and Company by 17.5% in the third quarter. Miller Global Investments LLC now owns 322 shares of the company's stock worth $373,000 after purchasing an additional 48 shares during the period. Polaris Financial Partners bought a new stake in shares of Eli Lilly and Company in the 3rd quarter worth approximately $551,000. GoalVest Advisory LLC grew its stake in shares of Eli Lilly and Company by 8.2% in the 3rd quarter. GoalVest Advisory LLC now owns 2,355 shares of the company's stock worth $2,725,000 after buying an additional 178 shares during the last quarter. Planning Strategies Inc. increased its position in Eli Lilly and Company by 128.6% during the 3rd quarter. Planning Strategies Inc. now owns 96 shares of the company's stock valued at $111,000 after buying an additional 54 shares in the last quarter. Finally, Private Client Services LLC raised its stake in Eli Lilly and Company by 3.4% during the third quarter. Private Client Services LLC now owns 911 shares of the company's stock valued at $1,055,000 after buying an additional 30 shares during the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Eli Lilly’s next-generation obesity treatment produced encouraging clinical-trial results, potentially adding another major growth product alongside Zepbound. The company also has multiple additional weight-loss candidates in development. Eli Lilly's Next Weight-Loss Drug Could Be Its Biggest Blockbuster Yet
• Positive Sentiment: The company said Foundayo was associated with a 57% reduction in the risk of developing type 2 diabetes, a result that could strengthen the potential market opportunity for Lilly’s metabolic-disease portfolio. Eli Lilly says Foundayo is associated with 57% reduction in type 2 diabetes risk
• Positive Sentiment: Lilly’s current weight-loss medicines generated approximately $14 billion in recent-quarter sales, highlighting strong demand in a market that could approach $100 billion within several years. Eli Lilly Just Announced Something Big
• Neutral Sentiment: Analysts emphasize Lilly’s competitive moat—drug innovation, patents, manufacturing capacity, brand strength, and its pipeline—but the stock’s elevated valuation means continued rapid growth may already be reflected in the shares. Eli Lilly’s Valuation Has Changed

Insider Transactions at Eli Lilly and Company

In other Eli Lilly and Company news, EVP Patrik Jonsson sold 6,500 shares of the firm's stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the transaction, the executive vice president directly owned 54,147 shares of the company's stock, valued at approximately $63,628,139.70. This trade represents a 10.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the business's stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the sale, the executive vice president owned 11,875 shares of the company's stock, valued at approximately $14,131,250. This represents a 29.63% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 13,500 shares of company stock worth $15,958,170 in the last ninety days. Insiders own 0.14% of the company's stock.

Eli Lilly and Company Stock Up 0.1%

LLY opened at $1,144.20 on Monday. The stock has a market capitalization of $1.08 trillion, a price-to-earnings ratio of 38.40, a PEG ratio of 1.40 and a beta of 0.46. The firm has a 50 day moving average price of $1,176.33 and a 200-day moving average price of $1,089.48. Eli Lilly and Company has a twelve month low of $783.85 and a twelve month high of $1,292.65. The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.40 by $1.98. The company had revenue of $22.97 billion for the quarter, compared to analysts' expectations of $20.82 billion. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The firm's quarterly revenue was up 47.7% on a year-over-year basis. During the same quarter last year, the company posted $6.31 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Equities research analysts forecast that Eli Lilly and Company will post 36.66 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on LLY shares. HSBC lifted their price target on Eli Lilly and Company from $850.00 to $940.00 and gave the stock a "reduce" rating in a research report on Thursday, September 10th. Royal Bank Of Canada lifted their target price on shares of Eli Lilly and Company from $1,250.00 to $1,500.00 and gave the stock an "outperform" rating in a report on Wednesday, July 8th. Wells Fargo & Company increased their price target on shares of Eli Lilly and Company from $1,280.00 to $1,330.00 and gave the company an "overweight" rating in a report on Thursday, August 6th. Wall Street Zen lowered shares of Eli Lilly and Company from a "strong-buy" rating to a "buy" rating in a report on Sunday, August 23rd. Finally, TD Cowen reaffirmed a "buy" rating and issued a $1,250.00 price objective on shares of Eli Lilly and Company in a research report on Tuesday, September 22nd. One investment analyst has rated the stock with a Strong Buy rating, twenty-five have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Eli Lilly and Company has an average rating of "Moderate Buy" and an average price target of $1,311.96.

About Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.